Apyx Medical (APYX) SVP exercises stock options to acquire 37,000 shares

Rhea-AI Filing Summary

Apyx Medical Corp Senior Vice President Moshe Citronowicz exercised a stock option to acquire 37,000 shares of common stock at $1.80 per share under the company’s 2015 Share Incentive Plan. Following the transaction, he directly owns 493,504 shares of Apyx Medical common stock, indicating a routine compensation-related increase in his equity stake.

Insights

Equity compensation and insider-transactions analyst

Routine option exercise adds 37,000 Apyx shares to SVP’s direct holdings.

The filing shows Senior Vice President Moshe Citronowicz exercised a stock option granted on March 16, 2016 to purchase 37,000 Apyx Medical common shares at $1.80 per share. This is coded as an exercise or conversion of derivative security, not an open-market purchase.

After the exercise, his direct ownership rises to 493,504 shares of common stock, according to the post-transaction balance. No sales, gifts, or tax-withholding dispositions are reported, and the derivative summary is empty, indicating this option grant was fully exercised in this filing.

The transaction appears as standard equity compensation usage rather than a discretionary market trade. Its scale, 37,000 shares relative to the reported 493,504 shares held afterward, suggests a routine adjustment in his equity position rather than a thesis-changing event for shareholders.

Insider Trade Summary

37,000 shares exercised/converted

Mixed 2 txns

Insider CITRONOWICZ MOSHE

Role Senior Vice President

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy)	37,000	$0.00	--
Exercise	Common Stock	37,000	$1.80	$67K

Holdings After Transaction: Stock option (right to buy) — 0 shares (Direct); Common Stock — 493,504 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CITRONOWICZ MOSHE

(Last) (First) (Middle)

C/O APYX MEDICAL CORPORATION

5115 ULMERTON ROAD

(Street)

CLEARWATER FL 33760

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apyx Medical Corp [ APYX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior Vice President

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		37,000	A	$1.8	493,504	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$1.8	03/15/2026		M			37,000	(1)	03/16/2036	Common Stock	37,000	$0	0	D

Explanation of Responses:

1. On March 15, 2026, the Reporting Person exercised his stock option awarded on March 16, 2016, to purchase 37,000 shares of the Issuer's common stock at a price of $1.80 per share pursuant to Issuer's 2015 Share Incentive Plan.

	/s/ Moshe Citronowicz	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apyx Medical (APYX) report for Moshe Citronowicz?

Apyx Medical reported that Senior Vice President Moshe Citronowicz exercised a stock option to acquire 37,000 common shares at $1.80 per share. The option was originally awarded on March 16, 2016 under the company’s 2015 Share Incentive Plan.

Did the Apyx Medical (APYX) insider Form 4 include any stock sales?

No, the Form 4 for Apyx Medical shows only an option exercise and corresponding acquisition of 37,000 common shares. There are no reported sales, gifts, or tax-withholding dispositions in this filing, indicating the shares were retained after exercise.

How many Apyx Medical (APYX) shares does Moshe Citronowicz own after this transaction?

Following the reported option exercise, Senior Vice President Moshe Citronowicz directly owns 493,504 shares of Apyx Medical common stock. This post-transaction balance comes from the Form 4’s non-derivative holdings table for his direct ownership position.

What was the exercise price on the Apyx Medical (APYX) stock options?

The exercised Apyx Medical stock option allowed purchase of 37,000 common shares at an exercise price of $1.80 per share. The option was granted on March 16, 2016 and exercised on March 15, 2026 under the 2015 Share Incentive Plan.

Is the Apyx Medical (APYX) insider transaction a market purchase or an option exercise?

The transaction is an option exercise, not an open-market purchase. The Form 4 uses code M, described as “exercise or conversion of derivative security,” reflecting use of a previously granted stock option to obtain 37,000 common shares at $1.80.

What plan covered the Apyx Medical (APYX) stock option exercised by the SVP?

The stock option exercised by Senior Vice President Moshe Citronowicz was granted under Apyx Medical’s 2015 Share Incentive Plan. According to the footnote, it was awarded on March 16, 2016 and exercised on March 15, 2026 for 37,000 shares at $1.80.